Rigetti Stock Soars 151% in a Year: Is It Still Worth Holding in 2026?

Rigetti Computing reported softer near-term fundamentals with Q3 revenue of $1.9 million (-18% YoY), gross margin compressing to 21% and operating expenses rising to $21 million, while maintaining nearly $600 million in cash and no debt. Management reaffirmed an ambitious roadmap (100+/150+ qubit targets in 2026 and a 1,000+ qubit platform in 2027) even as the company missed DARPA Phase B and faces lumpy, government-driven revenues; it secured a three-year $5.8 million Air Force Research Laboratory contract plus $5.7 million in Novera orders. Analysts see the name as speculative (Zacks Rank #3) with 2025 revenues expected to decline ~26.9% and EPS remaining deeply negative, and valuation appears rich (P/B ~22.4x vs. industry 6.1x), leaving the stock a monitoring candidate rather than a buy for risk-sensitive investors.

Analysis

Market structure: The quantum hardware race rewards well‑capitalized, milestone‑driven winners and punishes execution risk. Rigetti (RGTI) sits between research demand (Air Force $5.8M, Novera orders $5.7M) and speculative hardware expectations (100+ qubits in 2026, 1,000+ in 2027); well‑capitalized peers (IONQ) and niche players (QBTS) will capture near‑term commercial workloads, pushing smaller hardware vendors to compete on price and specialized contracts. Supply remains constrained by engineering cadence, so short‑term pricing power is weak but long‑term incumbency in chiplet IP and gov’t ties are scalable.

Risk assessment: Immediate tail risks include further public‑sector funding gaps and program losses (e.g., DARPA Phase B miss), operational setbacks on fidelity targets, or equity dilution if cash burn accelerates. Short term (weeks–months) expect volatility around quarterly prints and contract awards; key long‑term (2026–27) binary outcomes are demo/ship of 100–150 qubits with >=99.5% two‑qubit fidelity. Hidden dependency: federal funding cadence and DARPA/NIH award timing drive revenue lumpiness and valuation re‑rating.

Trade implications: For investors seeking exposure, size positions conservatively and tie adders to technical/cash triggers. Consider a 2% starter long RGTI (or 9–12 month LEAP calls) and scale to 4–6% only if the 100+‑qubit demo occurs by H1 2026 with measured fidelity ≥99.5% and QoQ revenue inflection; hedge via buying 12–18 month puts (collar) if holding outright. Relative trade: long IONQ vs short RGTI (notional 1:1) for 6–12 months given IONQ’s stronger commercialization; alternatively buy QBTS on momentum with tight stop at 25% drawdown.

Contrarian angles: Market may be over‑penalizing RGTI for a single DARPA miss—real option value in chiplet IP, government pipelines, and NVQLink partnerships is asymmetric if milestones hit. The consensus undervalues optionality: if RGTI demonstrates 150+ qubits with targeted fidelity by end‑2026, upside could be 2–3x from current levels; conversely, if federal funding tightens or hyperscalers internalize hardware (MSFT/GOOGL/AWS), downside to small caps is >50%. Monitor milestone dates, cash burn cadence, and major gov’t awards as binary triggers.

Key Decisions for Investors

• Establish a 2% portfolio long position in RGTI via stock or 12‑month LEAP calls; add to 4–6% only if RGTI publicly demos a 100+ qubit system by H1 2026 with median two‑qubit fidelity ≥99.5% and shows sequential revenue growth (QoQ) for two quarters.
• Initiate a pair trade: go long IONQ equal‑notional and short RGTI for 6–12 months to capture relative execution/monetization advantage; tighten pair if RGTI posts gross margin >40% or IONQ misses commercial bookings guidance.
• Put on a protective collar for any outright RGTI holding: buy 12‑18 month puts at ~30% OTM and sell near‑dated calls to finance premiums; unwind collar if cash runway falls below 12 months or RGTI announces no dilution plan within 60 days.
• Rotate 1–2% of speculative quantum hardware exposure into NVDA and MSFT (buy NVDA, MSFT) to capture secular quantum/AI infrastructure demand—use purchases on any tech selloff >10% as tactical entries.
• Avoid concentrated long exposure to QBTS despite momentum; if trading QBTS, use tight 20–25% stop losses and target short‑term alpha (weeks–3 months) rather than buy‑and‑hold given elevated momentum risk.